INmune Bio Inc.

INmune Bio (Nasdaq: INMB) is developing therapies that harness patient’s immune system to treat disease. Our focus is on #cancer, #Alzheimer’s disease.

[INmune Bio Inc. @INmuneBio]

$INMB announced FDA alignment on an integrated Phase 2b/3 registration pathway for #XPro1595 in early #alzheimers.

The FDA raised no objection to the development strategy and confirmed CDR-SB as the sole primary endpoint.

Full PR: https://t.co/oKSERMDNz4

#RegulatoryMilestone

[INmune Bio Inc. @INmuneBio]

As #RareDiseaseMonth comes to a close, #INmuneBio recognizes the millions affected by #raredisease and the ongoing need for innovation.

$INMB is advancing novel therapies for high unmet need conditions like #RDEB, a rare genetic disease with systemic impact beyond the skin.

[INmune Bio Inc. @INmuneBio]

On the @Xtalks Life Science Podcast, $INMB CEO David Moss discusses #INmuneBio’s dominant-negative inhibitor platform targeting chronic inflammation.

From #RDEB to #Alzheimers, learn how innate immunity may reshape treatment.

Listen on @YouTube: https://t.co/uVNLWBgtS8

[INmune Bio Inc. @INmuneBio]

February 14-21 is Alzheimer’s & Dementia Care Education Week, highlighting the role of education and innovation in care for those impacted by #Alzheimers.

With support from the @alzassociation, $INMB is advancing therapies targeting the underlying drivers of Alzheimer’s disease.

[INmune Bio Inc. @INmuneBio]

$INMB CEO & Co-Founder David Moss discusses INmune Bio’s precision immune modulation approach in Drug Discovery Online, highlighting the #CORDStrom and #XPro programs targeting harmful inflammation across rare and neurodegenerative diseases.

Read more: https://t.co/CE8iNDDVMC

[INmune Bio Inc. @INmuneBio]

#INmuneBio advances #CORDStrom for #RDEB with a key regulatory milestone.

$INMB has submitted its pre-submission package to the UK MHRA to streamline approval and shorten time-to-market.

Full PR: https://t.co/aJcrFtyfRT

#RareDisease #RegulatoryMilestone #INMB

[INmune Bio Inc. @INmuneBio]

#WorldCancerDay underscores the need for smarter, more precise approaches to disease.

#INmuneBio studies the innate immune system and how restoring immune balance may support new approaches to #cancer and other serious diseases.

$INMB #CancerResearch #Biotech

[INmune Bio Inc. @INmuneBio]

Recessive Dystrophic Epidermolysis Bullosa (#RDEB) is a rare genetic condition causing fragile skin, blisters, & challenges with eating, swallowing, joints, hair, & more.

$INMB is advancing research to improve the lives of those affected.

Learn more: https://t.co/gddJi9Y3yv

[INmune Bio Inc. @INmuneBio]

Today we’re spotlighting Mark Lowdell, CSO & CMO of #INmuneBio.

Serving in this role since 2015, Mark brings decades of leadership in translational #immunotherapy and cell-based medicine.

Learn more: https://t.co/xAPzF3NcFP

$INMB #EmployeeSpotlight

[INmune Bio Inc. @INmuneBio]

#INmuneBio issued a shareholder letter reviewing 2025 milestones & outlining 2026 strategic initiatives, highlighting progress with #XPro1595 in early #Alzheimers disease & continued advancement of #CORDStrom in #RDEB.

Read more: https://t.co/fLTQsT0Hng

$INMB #ShareholderUpdate

[INmune Bio Inc. @INmuneBio]

In a recent Rare Connection podcast, Mark Lowdell, CSO & Co-Founder of $INMB, discusses #CORDStrom, an investigational cell therapy for #RDEB.

The conversation highlights clinical progress, the regulatory path ahead, & patient impact.

Listen on @Spotify: https://t.co/IzS1sqd6OR

[INmune Bio Inc. @INmuneBio]

CEO David Moss shares his perspective on the #pharma advances that have shaped the industry over the past 30 years in a @pharmasalmanac roundtable, from biologics to advanced antibody engineering.

Full roundtable featuring industry leaders:

https://t.co/durlJYWS8z

$INMB

[INmune Bio Inc. @INmuneBio]

Spotlighting Cory Ellspermann, Interim CFO at #INmuneBio.

With nearly 30 years of financial leadership, Cory has been instrumental in strengthening $INMB's financial operations since joining in 2019.

Proud to highlight his #leadership.

Learn more: https://t.co/xAPzF3MEQh

[INmune Bio Inc. @INmuneBio]

In a new expert discussion from @ClinicalLeader1, researchers call for a shift beyond legacy clinical trial design.

David Moss, CEO and co-founder of $INMB, shares why #biology-driven endpoints and enrolling the right patients matter.

Full POV: https://t.co/aTbUZh1syF

[INmune Bio Inc. @INmuneBio]

$INMB is advancing therapies for RDEB, a #raredisease affecting skin, causing pain, wounds, & systemic issues.

Groups like @debraOfAmerica & @EBResearch support the #RDEB community, working toward better treatments and brighter futures.

Learn more: https://t.co/eSutmZGDUO

[INmune Bio Inc. @INmuneBio]

#INmune's CEO, David Moss, joins industry leaders in @pharmasalmanac's roundtable on how capital constraints are reshaping M&A and partnerships across pharma and CDMOs.

Read the full roundtable: https://t.co/tcOmo3OlTI

#INMB #PharmaTrends #Biotech

[INmune Bio Inc. @INmuneBio]

$INMB CEO David Moss spoke with @timsandle of @digitaljournal on late-stage programs targeting immune dysfunction & chronic inflammation.

He shares updates on CORDStrom for #epidermolysisbullosa, XPro for #Alzheimers, and upcoming milestones.

Read more: https://t.co/x93GmrTdop

[INmune Bio Inc. @INmuneBio]

Happy Holidays from #INmuneBio!

Wishing you a joyful season and a healthy, successful year ahead.

#INMB #HappyHolidays

[INmune Bio Inc. @INmuneBio]

Featuring Tara Lehner, Vice President of Clinical Operations at #INmuneBio.

Tara has 22+ years of experience across pharma, biotech, and CROs, and previously managed a $400 million strategic partnership portfolio.

Learn more about the $IMNB team: https://t.co/xAPzF3NcFP

[INmune Bio Inc. @INmuneBio]

#INmuneBio highlights #XPro & its potential to transform care for those affected by #Alzheimers.

Hear from $INMB's CEO on the progress following the Phase 2 trial& next steps in a recent #NanoCapPodcast.

Full episode: https://t.co/SUUVLfLGHV